Lilly Pulitzer is serving up a Valentine’s Day partnership with Lele Sadoughi, the New York-based accessories brand. Marking ...

Lilly Pulitzer’s treasured Sunshine Sale is back with splurge-worthy discounts and new styles perfect for the winter or ...

We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

John Carlsen has more than a decade of experience testing and reviewing home tech products, with a major focus on smart home security. He earned his BS in journalism from Utah Valley University.

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...

Pulitzer Prize-winning cartoonist Darrin Bell ... Bell's wife told the broadcaster in a brief phone interview to "pray for me and my children" but declined to comment further.

Tech entrepreneur and Tesla (TSLA, Financials) CEO Elon Musk's disclosure of using weight-loss pharmaceuticalsincluding Eli Lilly's (LLY, Financials) Mounjaro and Novo Nordisk's Ozempichas drawn ...

While Novo and Lilly both make attractive opportunities, recent news has me more bullish on one of them. Just to put into perspective how big a tailwind that weight loss space is for these ...